一项在既往接受过至少 1 线治疗的复发性或难治性多发性骨髓瘤受试者中比较Talquetamab(皮下注射)联合达雷妥尤单抗(皮下注射)和泊马度胺(Tal-DP)或Talquetamab(皮下注射)联合达雷妥尤单抗(皮下注射)(Tal-D)与达雷妥尤单抗(皮下注射)、泊马度胺和地塞米松(DPd)的III 期、随机研究
[Translation] A study comparing Talquetamab (subcutaneous injection) plus daratumumab (subcutaneous injection) and pomalidomide (Tal-DP) in subjects with relapsed or refractory multiple myeloma who had received at least 1 prior line of therapy. ) or Talquetamab (subcutaneous injection) combined with daratumumab (subcutaneous injection) (Tal-D) with daratumumab (subcutaneous injection), pomalidomide and dexamethasone (DPd) in Phase III, randomized study
本试验目的是分别比较Talquetamab 皮下给药联用达雷妥尤单抗皮下给药和泊马度胺(Tal-DP;A组)、Talquetamab 皮下给药联用达雷妥尤单抗皮下给药(Tal-D;C组)与达雷妥尤单抗皮下给药联用泊马度胺和地塞米松(DPd;B组)在复发或难治性多发性骨髓瘤患者中的疗效
[Translation] The purpose of this trial is to compare the subcutaneous administration of Talquetamab combined with subcutaneous administration of daratumumab with pomalidomide (Tal-DP; Group A), and the subcutaneous administration of Talquetamab combined with subcutaneous administration of daratumumab (Tal-DP; Group A). Tal-D; Arm C) combined with subcutaneous daratumumab plus pomalidomide and dexamethasone (DPd; Arm B) in patients with relapsed or refractory multiple myeloma
100 Clinical Results associated with Catalent (Shanghai) Clinical Trial Supplies Co. Ltd.
0 Patents (Medical) associated with Catalent (Shanghai) Clinical Trial Supplies Co. Ltd.
100 Deals associated with Catalent (Shanghai) Clinical Trial Supplies Co. Ltd.
100 Translational Medicine associated with Catalent (Shanghai) Clinical Trial Supplies Co. Ltd.